CA3168648A1 - Combination therapy for treating abnormal cell growth - Google Patents

Combination therapy for treating abnormal cell growth

Info

Publication number
CA3168648A1
CA3168648A1 CA3168648A CA3168648A CA3168648A1 CA 3168648 A1 CA3168648 A1 CA 3168648A1 CA 3168648 A CA3168648 A CA 3168648A CA 3168648 A CA3168648 A CA 3168648A CA 3168648 A1 CA3168648 A1 CA 3168648A1
Authority
CA
Canada
Prior art keywords
inhibitor
kras
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168648A
Other languages
English (en)
French (fr)
Inventor
Jonathan A. Pachter
Silvia COMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of CA3168648A1 publication Critical patent/CA3168648A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3168648A 2020-01-31 2021-01-28 Combination therapy for treating abnormal cell growth Pending CA3168648A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062968615P 2020-01-31 2020-01-31
US62/968,615 2020-01-31
US202063115433P 2020-11-18 2020-11-18
US63/115,433 2020-11-18
PCT/US2021/015401 WO2021154929A1 (en) 2020-01-31 2021-01-28 Combination therapy for treating abnormal cell growth

Publications (1)

Publication Number Publication Date
CA3168648A1 true CA3168648A1 (en) 2021-08-05

Family

ID=77079417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168648A Pending CA3168648A1 (en) 2020-01-31 2021-01-28 Combination therapy for treating abnormal cell growth

Country Status (11)

Country Link
US (1) US20230103007A1 (https=)
EP (1) EP4096671A4 (https=)
JP (1) JP2023513015A (https=)
KR (1) KR20230011908A (https=)
CN (1) CN115279376A (https=)
AU (1) AU2021213753A1 (https=)
BR (1) BR112022015161A2 (https=)
CA (1) CA3168648A1 (https=)
IL (1) IL295117A (https=)
MX (1) MX2022009347A (https=)
WO (1) WO2021154929A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
AU2020388848A1 (en) 2019-11-18 2022-05-26 Inxmed (Nanjing) Co., Ltd. Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
JP7582694B2 (ja) 2020-01-10 2024-11-13 イミューニヤリング コーポレーション Ｍｅｋ阻害剤及びその治療的使用
MX2022009612A (es) 2020-02-05 2022-09-19 Inxmed Nanjing Co Ltd Combinacion de bi853520 con farmacos quimioterapeuticos.
TW202206425A (zh) * 2020-08-03 2022-02-16 大陸商應世生物科技（南京）有限公司 化合物的固體形式
EP4284370A4 (en) * 2021-01-29 2024-12-11 Mirati Therapeutics, Inc. POLYTHERAPIES
EP4346826A4 (en) * 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
CN114133355B (zh) * 2021-11-29 2023-09-15 郑州大学第一附属医院 一种2-苯基-1h-苯并咪唑类衍生物及其应用
JP2024545147A (ja) * 2021-12-10 2024-12-05 ▲應▼世生物科技（南京）有限公司 腫瘍治療の医薬組合せ及び使用
WO2023108110A2 (en) * 2021-12-10 2023-06-15 Verastem, Inc. Combination therapy for treating abnormal cell growth
EP4488272A4 (en) * 2022-02-28 2026-02-25 Wigen Biomedicine Tech Shanghai Co Ltd COMPOUND USED AS A FAK INHIBITOR AND ITS USE
US20250262194A1 (en) * 2022-04-20 2025-08-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical for treating or preventing cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2023246869A1 (zh) * 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
KR20250052367A (ko) * 2022-08-24 2025-04-18 인엑스메드 (난징) 컴퍼니 리미티드 Fak 억제제와 미세소관 억제제의 약제학적 병용물 및 이의 용도
CN119947725A (zh) * 2022-09-30 2025-05-06 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途
KR20250152577A (ko) * 2023-01-06 2025-10-23 에라스카, 아이엔씨. Raf 억제제 및 kras g12c 억제제 조합 요법
CN115845065A (zh) * 2023-01-09 2023-03-28 江苏省原子医学研究所 Fn/fak通路抑制剂在制备提高甲状腺癌放射性碘治疗敏感性的药物中的用途
US12254987B2 (en) * 2023-03-23 2025-03-18 Certis Oncology Solutions, Inc. Artificial intelligence for identifying one or more predictive biomarkers
TW202440114A (zh) * 2023-03-31 2024-10-16 大陸商應世生物科技（南京）有限公司 提高大分子藥物在腫瘤組織中的濃度的方法
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法
WO2025106901A1 (en) * 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor
CN120284923A (zh) * 2024-01-11 2025-07-11 四川弘合生物科技有限公司 一种包含榄香烯和激酶抑制剂的药物
WO2025157162A1 (zh) * 2024-01-22 2025-07-31 应世生物科技(南京)有限公司 Fak抑制剂与kras g12c抑制剂的联用
WO2025261307A1 (zh) * 2024-06-17 2025-12-26 首药控股(北京)股份有限公司 治疗肿瘤的药物组合及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6835472B2 (ja) * 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
US11286469B2 (en) * 2017-11-09 2022-03-29 Wisconsin Alumni Research Foundation Combination chemotherapy for the treatment of cancer
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN114901286B (zh) * 2019-11-27 2024-05-10 特普医药公司 涉及二芳基巨环化合物的组合疗法

Also Published As

Publication number Publication date
EP4096671A1 (en) 2022-12-07
MX2022009347A (es) 2022-12-15
AU2021213753A1 (en) 2022-08-04
US20230103007A1 (en) 2023-03-30
WO2021154929A1 (en) 2021-08-05
JP2023513015A (ja) 2023-03-30
EP4096671A4 (en) 2024-02-28
BR112022015161A2 (pt) 2022-10-11
IL295117A (en) 2022-09-01
CN115279376A (zh) 2022-11-01
KR20230011908A (ko) 2023-01-25

Similar Documents

Publication Publication Date Title
US20230103007A1 (en) Combination therapy for treating abnormal cell growth
US12280050B2 (en) Therapeutic compositions, combinations, and methods of use
US20230330088A1 (en) Combination therapy for treating abnormal cell growth
US20250049792A1 (en) Combination therapy for treating abnormal cell growth
US20230201198A1 (en) Methods of treating abnormal cell growth
EP3102232A1 (en) Methods and compositions for treating abnormal cell growth

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250129

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250217

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250217

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250506

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260311